» Articles » PMID: 28957395

High MRNA Expression of Splice Variant SYK Short Correlates with Hepatic Disease Progression in Chemonaive Lymph Node Negative Colon Cancer Patients

Abstract

Objective: Overall and splice specific expression of Spleen Tyrosine Kinase (SYK) has been posed as a marker predicting both poor and favorable outcome in various epithelial malignancies. However, its role in colorectal cancer is largely unknown. The aim of this study was to explore the prognostic role of SYK in three cohorts of colon cancer patients.

Methods: Total messenger RNA (mRNA) expression of SYK, SYK(T), and mRNA expression of its two splice variants SYK short (S) and SYK long (L) were measured using quantitative reverse transcriptase (RT-qPCR) in 240 primary colon cancer patients (n = 160 patients with chemonaive lymph node negative [LNN] and n = 80 patients with adjuvant treated lymph node positive [LNP] colon cancer) and related to microsatellite instability (MSI), known colorectal cancer mutations, and disease-free (DFS), hepatic metastasis-free (HFS) and overall survival (OS). Two independent cohorts of patients with respectively 48 and 118 chemonaive LNN colon cancer were used for validation.

Results: Expression of SYK and its splice variants was significantly lower in tumors with MSI, and in KRAS wild type, BRAF mutant and PTEN mutant tumors. In a multivariate Cox regression analysis, as a continuous variable, increasing SYK(S) mRNA expression was associated with worse HFS (Hazard Ratio[HR] = 1.83; 95% Confidence Interval[CI] = 1.08-3.12; p = 0.026) in the LNN group, indicating a prognostic role for SYK(S) mRNA in patients with chemonaive LNN colon cancer. However, only a non-significant trend between SYK(S) and HFS in one of the two validation cohorts was observed (HR = 4.68; 95%CI = 0.75-29.15; p = 0.098).

Conclusion: In our cohort, we discovered SYK(S) as a significant prognostic marker for HFS for patients with untreated LNN colon cancer. This association could however not be confirmed in two independent smaller cohorts, suggesting that further extensive validation is needed to confirm the prognostic value of SYK(S) expression in chemonaive LNN colon cancer.

Citing Articles

Expression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K/AKT pathway.

Lin B, Wang Q, Wang X, Wei H, Nie X, Li L Sci Rep. 2024; 14(1):29080.

PMID: 39580521 PMC: 11585633. DOI: 10.1038/s41598-024-80579-9.


Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets.

Dangelmaier C, Vari H, Vajipayajula D, Elzoheiry M, Wright M, Iyer A Platelets. 2024; 35(1):2369766.

PMID: 38904212 PMC: 11322839. DOI: 10.1080/09537104.2024.2369766.


Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.

Li N, Jia W, Wang J, Shao Q, Feng X, Li Z EPMA J. 2024; 15(2):345-373.

PMID: 38841624 PMC: 11147996. DOI: 10.1007/s13167-024-00366-4.


Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets.

Singh P, Dangelmaier C, Vari H, Tsygankov A, Kunapuli S Platelets. 2023; 34(1):2249549.

PMID: 37661351 PMC: 10502920. DOI: 10.1080/09537104.2023.2249549.


Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells.

Denis V, Cassagnard N, Del Rio M, Cornillot E, Bec N, Larroque C PLoS One. 2022; 17(9):e0274390.

PMID: 36103569 PMC: 9473616. DOI: 10.1371/journal.pone.0274390.


References
1.
Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M . SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. PLoS One. 2014; 9(2):e87610. PMC: 3921124. DOI: 10.1371/journal.pone.0087610. View

2.
Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

3.
Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C . Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 2014; 74(6):1845-56. PMC: 3959256. DOI: 10.1158/0008-5472.CAN-13-2104. View

4.
Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R . Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15):1151-6. PMC: 3735463. DOI: 10.1093/jnci/djt173. View

5.
Sieuwerts A, Lyng M, Meijer-Van Gelder M, de Weerd V, Sweep F, Foekens J . Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. Mol Oncol. 2014; 8(8):1679-89. PMC: 5528606. DOI: 10.1016/j.molonc.2014.07.003. View